Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
A Phase III Randomized Study of Zolendronate Bisphosphonate Therapy for the Prevention of Bone Loss in Men With Prostate Cancer Receiving Long-Term Androgen Deprivation
Sponsor: Northwestern University
This PHASE3 trial investigates Osteoporosis and Prostate Cancer and is currently terminated or withdrawn. Northwestern University leads this study, which shows 10 recorded versions since 2003 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE3
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE3
▶ Show 5 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Jun 2019 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Northwestern University
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Chicago, United States